Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials

Cancer Treatment Reviews ◽

10.1016/j.ctrv.2017.04.005 ◽

2017 ◽

Vol 57 ◽

pp. 8-15 ◽

Cited By ~ 28

Author(s):

C. Solinas ◽

M. Ceppi ◽

M. Lambertini ◽

M. Scartozzi ◽

L. Buisseret ◽

...

Keyword(s):

Breast Cancer ◽

Neoadjuvant Chemotherapy ◽

Randomized Controlled Trials ◽

Meta Analysis ◽

Tumor Infiltrating Lymphocytes ◽

Controlled Trials ◽

Her2 Positive ◽

Randomized Controlled ◽

Infiltrating Lymphocytes ◽

Positive Breast Cancer

Download Full-text

Is it safe to give anthracyclines concurrently with trastuzumab in neo-adjuvant or metastatic settings for HER2-positive breast cancer? A meta-analysis of randomized controlled trials

Medical Oncology ◽

10.1007/s12032-014-0340-x ◽

2014 ◽

Vol 31 (12) ◽

Cited By ~ 6

Author(s):

Feng Du ◽

Peng Yuan ◽

Wenjie Zhu ◽

Jiayu Wang ◽

Fei Ma ◽

...

Keyword(s):

Breast Cancer ◽

Randomized Controlled Trials ◽

Meta Analysis ◽

Controlled Trials ◽

Her2 Positive ◽

Randomized Controlled ◽

Her2 Positive Breast Cancer ◽

Positive Breast Cancer

Download Full-text

Tumor infiltrating lymphocytes in HER2-positive breast cancer patients treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of published randomized clinical trials

Annals of Oncology ◽

10.1093/annonc/mdx138.004 ◽

2017 ◽

Vol 28 ◽

pp. i11

Author(s):

C. Solinas ◽

M. Ceppi ◽

M. Lambertini ◽

M. Scartozzi ◽

S. Garaud ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trials ◽

Neoadjuvant Chemotherapy ◽

Randomized Clinical Trials ◽

Meta Analysis ◽

Tumor Infiltrating Lymphocytes ◽

Breast Cancer Patients ◽

Her2 Positive ◽

Infiltrating Lymphocytes ◽

Positive Breast Cancer

Download Full-text

Short-duration versus 1-year adjuvant trastuzumab in early HER2 positive breast cancer: A meta-analysis of randomized controlled trials

Cancer Treatment Reviews ◽

10.1016/j.ctrv.2019.02.003 ◽

2019 ◽

Vol 75 ◽

pp. 12-19 ◽

Cited By ~ 13

Author(s):

Lujia Chen ◽

Wenqi Zhou ◽

Xiaolei Hu ◽

Man Yi ◽

Changsheng Ye ◽

...

Keyword(s):

Breast Cancer ◽

Randomized Controlled Trials ◽

Short Duration ◽

Meta Analysis ◽

Controlled Trials ◽

Her2 Positive ◽

Adjuvant Trastuzumab ◽

Randomized Controlled ◽

Her2 Positive Breast Cancer ◽

Positive Breast Cancer

Download Full-text

Significantly higher pathologic complete response (pCR) after the concurrent use of trastuzumab and anthracycline-based neoadjuvant chemotherapy for HER2-positive breast cancer: Evidence from a meta-analysis of randomized controlled trials

Journal of Cancer ◽

10.7150/jca.24701 ◽

2018 ◽

Vol 9 (17) ◽

pp. 3168-3176 ◽

Cited By ~ 1

Author(s):

Yu-tuan Wu ◽

Zhou Xu ◽

Bilal Arshad ◽

Jiu-song Wu ◽

Ke Zhang ◽

...

Keyword(s):

Breast Cancer ◽

Neoadjuvant Chemotherapy ◽

Meta Analysis ◽

Pathologic Complete Response ◽

Complete Response ◽

Controlled Trials ◽

Her2 Positive ◽

Randomized Controlled ◽

Concurrent Use ◽

Positive Breast Cancer

Download Full-text

Tumor-infiltrating lymphocytes in HER2-positive breast cancer patients treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or the combination: a meta-analysis of published randomized clinical trials

The Breast ◽

10.1016/s0960-9776(17)30336-3 ◽

2017 ◽

Vol 32 ◽

pp. S105

Keyword(s):

Breast Cancer ◽

Clinical Trials ◽

Neoadjuvant Chemotherapy ◽

Randomized Clinical Trials ◽

Meta Analysis ◽

Tumor Infiltrating Lymphocytes ◽

Breast Cancer Patients ◽

Her2 Positive ◽

Infiltrating Lymphocytes ◽

Positive Breast Cancer

Download Full-text

Optimal threshold for stromal tumor-infiltrating lymphocytes: its predictive and prognostic value in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant chemotherapy

Breast Cancer Research and Treatment ◽

10.1007/s10549-015-3617-7 ◽

2015 ◽

Vol 154 (2) ◽

pp. 239-249 ◽

Cited By ~ 13

Author(s):

Shiwei Liu ◽

Xuening Duan ◽

Ling Xu ◽

Ling Xin ◽

Yuanjia Cheng ◽

...

Keyword(s):

Breast Cancer ◽

Neoadjuvant Chemotherapy ◽

Prognostic Value ◽

Tumor Infiltrating Lymphocytes ◽

Optimal Threshold ◽

Her2 Positive ◽

Her2 Positive Breast Cancer ◽

Predictive And Prognostic Value ◽

Infiltrating Lymphocytes ◽

Positive Breast Cancer

Download Full-text

Trastuzumab As A Therapy Versus Other Treatment Regimens In Patients With HER2 Positive Breast Cancer: A Systematic Review of Randomized Controlled Trials

Value in Health ◽

10.1016/j.jval.2017.08.120 ◽

2017 ◽

Vol 20 (9) ◽

pp. A418

Author(s):

Sk Yerram ◽

HR Gadi ◽

K Kethireddy ◽

R Thatavarti

Keyword(s):

Breast Cancer ◽

Systematic Review ◽

Randomized Controlled Trials ◽

Controlled Trials ◽

Her2 Positive ◽

Treatment Regimens ◽

Randomized Controlled ◽

Her2 Positive Breast Cancer ◽

Positive Breast Cancer

Download Full-text

Short-term outcomes of neoadjuvant hormonal therapy versus neoadjuvant chemotherapy in breast cancer: systematic review and meta-analysis of randomized controlled trials

Expert Review of Anticancer Therapy ◽

10.1080/14737140.2017.1301208 ◽

2017 ◽

Vol 17 (4) ◽

pp. 327-334 ◽

Cited By ~ 5

Author(s):

Lei Huang ◽

A-Man Xu

Keyword(s):

Breast Cancer ◽

Systematic Review ◽

Neoadjuvant Chemotherapy ◽

Randomized Controlled Trials ◽

Hormonal Therapy ◽

Meta Analysis ◽

Controlled Trials ◽

Short Term ◽

Neoadjuvant Hormonal Therapy ◽

Randomized Controlled

Download Full-text

Abstract P4-14-17: Prognostic value of tumor-infiltrating lymphocytes in residual tumors after neoadjuvant chemotherapy concomitant with trastuzumab for HER2-positive breast cancer

10.1158/1538-7445.sabcs15-p4-14-17 ◽

2016 ◽

Author(s):

S Kurozumi ◽

K Inoue ◽

H Matsumoto ◽

Y Hayashi ◽

K Tozuka ◽

...

Keyword(s):

Breast Cancer ◽

Neoadjuvant Chemotherapy ◽

Prognostic Value ◽

Tumor Infiltrating Lymphocytes ◽

Her2 Positive ◽

Her2 Positive Breast Cancer ◽

Infiltrating Lymphocytes ◽

Positive Breast Cancer

Download Full-text

Six Months vs. 12 Months of Adjuvant Trastuzumab Among Women With HER2-Positive Early-Stage Breast Cancer: A Meta-Analysis of Randomized Controlled Trials

Frontiers in Oncology ◽

10.3389/fonc.2020.00288 ◽

2020 ◽

Vol 10 ◽

Author(s):

Huan Deng ◽

Xianghui Du ◽

Li Wang ◽

Ming Chen

Keyword(s):

Breast Cancer ◽

Randomized Controlled Trials ◽

Early Stage ◽

Meta Analysis ◽

Early Stage Breast Cancer ◽

Controlled Trials ◽

Her2 Positive ◽

Adjuvant Trastuzumab ◽

Randomized Controlled

Download Full-text